Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
Abroad (travel likely)RecruitingPHASE3
Conditions
Colorectal Cancer · Metastatic Colorectal Cancer · RAS Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ospedale San Salvatore, Coppito, L'Aquila, Italy
Ospedale Civile di Guastalla, Guastalla, Reggio Emilia, Italy
AUSL/IRCCS di Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy
Azienda ULSS 3 Serenissima, Mirano, VE, Italy
Contact: Study coordinator (Giuseppe Azzarello, MD) · giuseppe.azzarello@aulss3.veneto.it · +39 041 2608482
Study leads
Erika Gervasi
Study Chair
AUSL IRCCS Reggio Emilia
Irene De Simone
Study Chair
Istituto Di Ricerche Farmacologiche Mario Negri